Abstract Icotinib significantly improves survival and prognosis in patients with epidermal growth factor receptor (EGFR)-sensitive non-small cell lung cancer (NSCLC). It is generally well-tolerated, with treatment-related myeloid neoplasm (t-MN) being a rare adverse reaction.
Huiling Huang
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Huiling
Contact Huiling, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack